LATEST ON BIZNEWS RADIO: Chris Logan: Coronation’s shares tanking on Peche’s “explosive” disclosures – company urgently needs to respond. (For Spotify, click here)
There’s been plenty about Ivermectin in the Premium newsletter this week. First, that 13 month old interview with Dr Nathi Mdladla et al which brought us a one week “strike” in adding fresh content to the BizNews TV channel on YouTube. Then yesterday’s praise of an apparent American change of heart.
___STEADY_PAYWALL___I’m in awe of the spontaneous response we receive from our tribe. Quite a few of whom dug deeper after yesterday’s note, including Richard Muller who sent me the NIH’s 456 page document with its revised “Covid-19 Treatment Guidelines.” Thankfully, he did the actual reading.
Richard pointed me to Page 210 of the tome which reads “The Panel recommends against the use of Ivermectin for the treatment of COVID-19 except in clinical trials.” So despite listing the drug on a prominent page, the US Dept of Health remains 100% aligned with wording of the WHO.
As a postscript, Richard added: “I’m neither for not against. I do however know quite a few people who believe they are alive only due to Ivermectin. Just as I know none who have been harmed by it.” Solid common sense from our investigative community member. Sense that’s not so common, however, in the portals of medical power.
More for you to read today:
- A reply to RW Johnson. Douglas Gibson says the DA leader, like all of us, does sometimes say silly things, but he is doing a creditable job at a critical time.
- Queen Elizabeth II, Longest-Reigning British Monarch, Dies. Her seven decades on the throne spanned the dismantling of an empire and a shrinking of the U.K.’s role in the world.
- ECB Raises Interest Rates by a Historic 0.75 Point as Europe Stares at Recession. European Central Bank intensifies fight against inflation even as Europe’s prospects darken amid economic war with Russia.
- U.K. Looks Like a Basket Case, but Markets Haven’t Lost Faith Yet. This might not sound like a natural place to invest, but everything has a price.
NB FOR YOUR WALL STREET JOURNAL ACCESS…
As a Premium subscriber you are entitled to full membership of wsj.com (normal price $29 a month). Be sure to action your access through the Premium link on the BizNews website. Because of The Wall Street Journal’s credential requirements, be sure to create a password which has at least 8 characters and includes at least one letter and one number – NB it MAY NOT contain any special characters (ie #, !, @ etc). To maintain access to WSJ.com, you MUST enter our partner’s website via Biznews Premium at least once a month. A final PS, if you had previously signed up for WSJ you’ll need to clear the cookies from your device. Our helpdesk can assist –[email protected].
